The Mumbai based Coral Laboratories set to commence the second phase of its expansion plan before March 2007 involving a total outlay of Rs 25 crore. The company's Beta lactum plant is located at Selaqui in Uttaranchal. Corel has already commissioned its non Beta-lactum plant during 2006.
While talking with Pharmabiz, S Ramamurthy, director, Coral Laboratories, said, "Currently, we are generating more sales revenue from our partly commissioned plant at Uttaranchal. But we are hoping that from phase II, we will generate significant higher sales revenue. We have two operational plants one at Baroda and second at Daman. However, the sales revenue of Uttaranchal plant is more than the other two plants. "
The company's new plant will have manufacturing activities beside injectables. It has a wide range of products in key therapeutic segments such as: antibiotics, antacid, anti asthmatic, cough expectorant, anti-bacterial, anti-Ulcer, anathematic, cardiac medicines, vitamin supplement, anti-spasmodic, anti-protozual, tropical preparations, iron supplement, analgesic, anti-amoebic, herbal medicine, anti-inflammatory, antipyretic and cough suppressant. Presently, the company is also undertaking jobs on third party basis and exports to various parties.
The company's state-of-the-art manufacturing facilities meet the stringent and over flexible quality requirements. Its Uttaranchal project is preparing to obtain UK MHRA and US FDA approvals. Corel is a global player and its products are available around ten countries including Sri Lanka, Nigeria, Kenya, Vietnam, etc. The company's products are also under registration in more than 20 countries.
"We are also looking for the Joint Ventures and contract manufacturing. We are in a position to add another Rs 12 crore to the turnover in the current year and the same will moved up by Rs 20 crore and Rs 30 crore during 2007-08 and 2008-09 respectively. The newly acquired DWD Marketing division will add another Rs 6 core in revenues and we will not have any gestation period," he added.